In its first stage will participate in 200 healthy people who are between 18 and 55 years.
The Institute Paul Ehrlich, the body in charge of the development of vaccines and medicines in Germany, has approved to conduct the first clinical trials in the territory to German for a vaccine against the coronavirus, according to has been reported this April 22.
In a first stage, in this trial will participate 200 healthy people between the ages of 18 and 55 years of age and will be vaccinated with “one of several variants of the vaccine are slightly modified”.
The specialists will observe your condition for a period of time and, subsequently, will begin the second phase of testing, which will involve other volunteers with the same age range.
The approval of this initiative is “the result of a careful evaluation“of the candidates in relation to the potential benefits and risks that are borne when testing this vaccine, developed by the company BioNTech.
Also, the leaders of the Institute, Paul Ehrlich estimated that this step is “an important milestone“to have “a safe and effective vaccine against the covid-19” is used in the population of Germany and other countries.
The development of a vaccine against the coronavirus is a goal of a number of countries around the world.
In Russia announced the start of tests of a vaccine on volunteers. In the united States and China are also conducting tests of vaccines.
For his part, the secretary of health of Uk, Matt Hancock, announced that human trials of a possible vaccine against the coronavirus developed at the University of Oxford begin this Thursday. Professor of vaccination of the University, Sarah Gilbert, reported that the inoculation could be ready for use in Septemberwhen usually the process would involve approximately 18 months.
Last week, the director general of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, stated that three vaccines against the covid-19 were in the same stage of testing with humans and other 70 were in development mode.
If you liked it, do share it with your friends!